The settlement removes a key litigation overhang and provides long-term clarity on SUNOSI generic entry. Expect positive stock reaction. Monitor FTC/DOJ review, but such settlements are routine and likely to clear. This bolsters Axsome's revenue visibility and may support upward earnings revisions.
Price Chart
Executive Summary
Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier than March 2040 (or September 2040 with pediatric exclusivity). This removes a major overhang and secures SUNOSI's exclusivity for over 14 years, significantly de-risking the product's long-term revenue stream.
Key Facts
- All outstanding SUNOSI patent litigation resolved via settlement with the only remaining first-to-file generic applicant.
- Five companies granted the right to sell generic SUNOSI beginning on or after September 1, 2040 (if pediatric exclusivity granted) or March 1, 2040 (if not), subject to FDA approval.
- No other SUNOSI patent litigation remains pending.
- Settlement will be submitted to FTC and DOJ for review.
Financial Impact
No specific financial terms disclosed, but extension of SUNOSI exclusivity to 2040 protects a key product generating significant revenue (SUNOSI is approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea). Generic entry delayed by over 14 years.
Risk Factors
- FTC or DOJ could challenge the settlement, though typical 'pay-for-delay' risks appear low given the broad licensing structure.
- If pediatric exclusivity is not granted, generic entry moves to March 2040 (still well in the future).
- SUNOSI revenue could be impacted by other competitive threats or label changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254708 |
| Document: axsm-ex99_1.htm | 0001193125-26-254708 |
| Document: 0001193125-26-254708-index-headers.html | 0001193125-26-254708 |
| Document: 0001193125-26-254708-index.html | 0001193125-26-254708 |
| Document: 0001193125-26-254708.txt | 0001193125-26-254708 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.95 (−17.57%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.95 (−19.89%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.95 (−25.51%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.95 (−28.92%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.95 (−29.15%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.95 (−27.57%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.95 (−30.17%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.95 (−30.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access